Utama › Karsinoma Epitel Ovari
Kajian klinikal Karsinoma Epitel Ovari sedang mengambil peserta di AS
26 kajian untuk Karsinoma Epitel Ovari sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Boston, MA8 kajian
- Durham, NC8 kajian
- Chicago, IL7 kajian
- San Diego, CA7 kajian
- New York City, NY7 kajian
- Philadelphia, PA6 kajian
- Baltimore, MD6 kajian
- Houston, TX6 kajian
- Cleveland, OH6 kajian
- Edison, NJ5 kajian
- Los Angeles, CA5 kajian
- Minneapolis, MN5 kajian
- Portland, OR5 kajian
- Salt Lake City, UT5 kajian
- New Haven, CT4 kajian
- St. Louis, MO4 kajian
- San Antonio, TX4 kajian
- Birmingham, AL4 kajian
- Seattle, WA4 kajian
- Arlington, VA4 kajian
- Dallas, TX4 kajian
- Queens, NY4 kajian
- Rochester, MN3 kajian
- Mountain View, CA3 kajian
- Oklahoma City, OK3 kajian
- Columbus, OH3 kajian
- Clifton, NJ3 kajian
- Nashville, TN3 kajian
- Grand Rapids, MI3 kajian
- Sioux Falls, SD3 kajian
- New Orleans, LA3 kajian
- Billings, MT3 kajian
- Washington, DC3 kajian
- West Palm Beach, FL3 kajian
- Dayton, OH3 kajian
- Indianapolis, IN3 kajian
- Providence, RI3 kajian
- Aurora, CO3 kajian
- San Francisco, CA3 kajian
- Shreveport, LA3 kajian
Mengikut negeri
- Alabama4 kajian
- Arizona4 kajian
- California10 kajian
- Colorado4 kajian
- Connecticut4 kajian
- Florida11 kajian
- Georgia3 kajian
- Illinois8 kajian
- Indiana3 kajian
- Louisiana4 kajian
- Maryland7 kajian
- Massachusetts9 kajian
- Michigan5 kajian
- Minnesota7 kajian
- Missouri5 kajian
- Montana3 kajian
- New Jersey9 kajian
- New York10 kajian
- North Carolina9 kajian
- Ohio10 kajian
- Oklahoma3 kajian
- Oregon6 kajian
- Pennsylvania10 kajian
- Rhode Island3 kajian
- South Dakota3 kajian
- Tennessee6 kajian
- Texas12 kajian
- Utah5 kajian
- Virginia6 kajian
- Washington6 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 1 Okt 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05867251Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT06915025A Study of Isoquercetin in People With Ovarian Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07303894ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 17 Ogo 2026 · NCT07764133Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Mengambil peserta
Umur 18 ke atas · Wanita · Dikemas kini 6 Ogo 2026 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Mengambil peserta
Umur 18 ke atas · Wanita · Dikemas kini 1 Jul 2026 · NCT05429970[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Mengambil pesertaFasa 1/2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 23 Jun 2026 · NCT07432633CT-95 in Advanced Cancers Associated With Mesothelin Expression
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT06756035Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 19 Mei 2026 · NCT06305299Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT05297734A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 7 Apr 2026 · NCT04516447A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 3 Feb 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Mengambil pesertaKajian pemerhatian
Umur 30 ke atas · Wanita · Dikemas kini 16 Sep 2025 · NCT04794322A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Ogo 2025 · NCT04429542A Beta-only IL-2 ImmunoTherapY Study
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2025 · NCT05086692BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mac 2025 · NCT04196257Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 80 · Wanita · Dikemas kini 28 Feb 2025 · NCT00005095Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.